TY - BOOK AU - Tegos,George AU - Mylonakis,Eleftherios ED - C.A.B. International, TI - Antimicrobial drug discovery: emerging strategies T2 - Advances in molecular and cellular microbiology AV - RM267 .A554 2012eb U1 - 615.7/92 23 PY - 2012/// CY - Wallingford, Oxfordshire, UK PB - CABI KW - Anti-infective agents KW - Development KW - Drug development KW - Drug resistance KW - Anti-Infective Agents KW - pharmacology KW - Drug Design KW - Disease Models, Animal KW - High-Throughput Screening Assays KW - methods KW - Photosensitizing Agents KW - Prion, Viral, Bacterial and Fungal Pathogens of Humans, (New March 2000) KW - Animal Models of Human Diseases, (New March 2000) KW - Animal and in vitro Models for Pharmaceuticals, (New March 2000) KW - Non-drug Therapy and Prophylaxis of Humans, (New March 2000) KW - Biosensors and Biological Nanotechnology, (New June 2002) KW - Biochemistry and Physiology of Microorganisms, (New March 2000) KW - Bacteria KW - cabt KW - Fungi KW - Acetyl-CoA carboxylase KW - Animal models KW - Antibacterial agents KW - Antifungal agents KW - Bacterial diseases KW - Biofilms KW - Disease models KW - Drug susceptibility KW - Drug targets KW - Human diseases KW - Laboratory animals KW - Lipopolysaccharides KW - Mycoses KW - Peptide antibiotics KW - Phototherapy KW - Resistance mechanisms KW - Structure activity relationships KW - Electronic books N1 - Includes bibliographical references and index; Emerging discovery strategies : an evolving necessity / Anthony R. Ball and George P. Tegos -- The antibiotic crisis / Arnold L. Demain and Jaroslav Spizek -- Structure, genetic regulation, physiology and function of the AcrAB-TolC efflux pump of escerichia coli and salmonella / Leonard Amaral ... [et al.] -- Small molecule efflux pump inhibitors from natural products as a potential source of antimicrobial agents / Sanjay M. Jachak ... [et al.] -- Fungal efflux-mediated resistance : from targets to inhibitors / Brian C. Monk ... [et al.] -- Vacuolar ATPase (V-ATPase) : a model proton pump for antifungal drug discovery -- Karlett J Parra -- Drug tolerance, persister cells and drug discovery / Kim Lewis -- Inhibition of quorum sensing as a novel antimicrobial strategy -- Gilles Brackman, Hans J. Nelis and Tom Coenye -- Filamentous temperature-sensitive mutant Z (FtsZ) protein as an antibacterial target / Jaroslaw M. Boberek ... [et al.] -- Lysostaphin : a silver bullet for staph / John F. Kokai-Kun -- Strategies to identify modified ribosomally synthesized antimicrobials -- Alan J. Marsh ... [et al.] -- QSAR based discovery of antimicrobial peptides active against multidrug resistant bacteria / Christopher D. Fjell ... [et al.] -- Acetyl-CoA carboxylase as a target for antibacterial development / Grover L. Waldrop -- Underexploited targets in LPS biogenenesis for the design of antibacterials / Laura Cipolla ... [et al.] -- Predicting and dissecting biomolecular interactions by information-driven docking / Panagiotis Kastritsis & Alexandre M.J.J Bonvin -- Anti-fungals and anti-fungal drug discovery / Richard Calderone ... [et al.] -- Pathosystematic studies and the rational design of antifungal interventions / Elaine M Bignell and Darius Armstrong-James -- In vivo high-throughput antimicrobial discovery screens utilizing caenorhabditis elegans as an alternative host / Jeffrey J. Coleman and Eleftherios Mylonakis -- Drosophila melanogaster as a versatile model for discovery of drugs effective against human microbe-induced infection and pathology / Yiorgos Apidianakis and Dimitrios P. Kontoyiannis -- Antimicrobial photosensitizers - harnessing the power of light to treat infections / Sulbha K Sharma, Tianhong Dai and Michael R Hamblin -- Nanoparticle platforms for antimicrobial therapy / David Trofa, Joshua D. Nosanchuk -- Antimicrobial activity of carbon nanotubes / Shaobin Liu, Yuan Chen; Access limited to subscribing institution; Also available in print format N2 - This book, inclusive of 22 chapters, describes novel approaches currently used for antimicrobial drug discovery, focusing on agents for use against bacterial and fungal pathogens. Specific chapters discuss: (1) concepts relevant to drug resistance; (2) microbial mechanisms related to efflux pumps and studies on their potential inhibitors; (3) impact of multidrug tolerance of biofilms and persister cells; (4) bacterial quorum-sensing inhibition; (5) inhibition of the bacterial filamentous temperature-sensitive mutant Z (FtsZ); (6) antibacterial properties of lysostaphin; (7) strategies to identify modified ribosomally synthesized antimicrobials; (8) quantitative structure-activity relationship studies of novel antimicrobial peptides; (9) bacterial acetyl-CoA carboxylase and lipopolysacharide as drug targets for antibiotic development; (10) pathosystematic systems biology for the rational design of novel antifungal compounds; (11) specific animal models for novel antimicrobial discovery; and (12) new antimicrobial technology platforms such as antimicrobial photodynamic therapy and carbon nanotubes UR - https://dx.doi.org/10.1079/9781845939434.0000 ER -